NASDAQ: BEATHeartbeam Inc Stock
$1.33+0.11 (+9.02%)
Updated Feb 13, 2026
BEAT Price
$1.33
Fair Value Price
$0.09
Market Cap
$45.81M
52 Week Low
$0.54
52 Week High
$4.00
P/E
-2.02x
P/B
112.83x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
6.08
Operating Cash Flow
-$15M
Beta
1.01
Next Earnings
Mar 19, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BEAT Overview
HeartBeam, Inc., provides telemedicine solutions to detect and monitor cardiac disease remotely (outside a healthcare facility). Its product is a credit card-sized electrocardiogram machine and a cloud-based diagnostic software system. HeartBeam was incorporated in 2015 and is headquartered in Santa Clara, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BEAT's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
BEAT
Ranked#45 of 45
Ranked#45 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.50 | A | |
| $8.75 | A | |
| $99.71 | A |
Be the first to know about important BEAT news, forecast changes, insider trades & much more!
BEAT News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BEAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BEAT ($1.33) is overvalued by 1,390.88% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BEAT ($1.33) is not significantly undervalued (1,390.88%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BEAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BEAT due diligence checks available for Premium users.
Valuation
BEAT fair value
Fair Value of BEAT stock based on Discounted Cash Flow (DCF)
Price
$1.33
Fair Value
$0.09
Overvalued by
1,390.88%
BEAT ($1.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BEAT ($1.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BEAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BEAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.02x
Industry
27.15x
Market
43.92x
BEAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
112.83x
Industry
3.22x
BEAT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BEAT's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
BEAT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.9M
Liabilities
$2.5M
Debt to equity
6.08
BEAT's short-term liabilities ($2.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BEAT's short-term assets ($2.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BEAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
$1.7M
Financing
$45.0k
BEAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BEAT vs Health Information Service Stocks
Heartbeam Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.